NZ329156A - A method of treating harmful effects of an endogenous HGF using a modified HGf which in non-glycosylated - Google Patents

A method of treating harmful effects of an endogenous HGF using a modified HGf which in non-glycosylated

Info

Publication number
NZ329156A
NZ329156A NZ329156A NZ32915697A NZ329156A NZ 329156 A NZ329156 A NZ 329156A NZ 329156 A NZ329156 A NZ 329156A NZ 32915697 A NZ32915697 A NZ 32915697A NZ 329156 A NZ329156 A NZ 329156A
Authority
NZ
New Zealand
Prior art keywords
hgf
modified
endogenous
glycosylated
harmful effects
Prior art date
Application number
NZ329156A
Inventor
Mathew Alexander Vadas
Angel Francisco Lopez
Mary Frances Shannon
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of NZ329156A publication Critical patent/NZ329156A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This use of a modified HGF (haemopoietic growth factor) is in medicaments for ameliorating the aberrant effects of an endogenous HGF in a mammal. The modified HGF used is characterised by being in an unglycosylated form and comprising a sequence of amino acids within a first a-helix where one of the amino acids having acidic properties is substituted with a basic amino acid residue.
NZ329156A 1993-07-28 1997-11-11 A method of treating harmful effects of an endogenous HGF using a modified HGf which in non-glycosylated NZ329156A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM018693 1993-07-28
AUPM477294 1994-03-30
NZ26976697 1997-11-11

Publications (1)

Publication Number Publication Date
NZ329156A true NZ329156A (en) 2000-07-28

Family

ID=27157732

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ329156A NZ329156A (en) 1993-07-28 1997-11-11 A method of treating harmful effects of an endogenous HGF using a modified HGf which in non-glycosylated

Country Status (1)

Country Link
NZ (1) NZ329156A (en)

Similar Documents

Publication Publication Date Title
EP0292291A3 (en) Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
ATE140969T1 (en) IL-3 WITH ADDITIONAL CYSTEINE RESIDUE AND CHEMICAL MODIFICATIONS THEREOF
DE69534468D1 (en) GROWTH DIFFERENTIATION FACTOR 11
IL143481A0 (en) Glp-1 analogues
MX9703643A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
PL349468A1 (en) Analogues of glp-1
ATE80166T1 (en) PROCESS FOR ISOLATION OF RECOMBINANT POLYPEPTIDES IN BIOLOGICALLY ACTIVE FORM.
ES8802235A1 (en) Structure and properties of modified interferons.
DE59810596D1 (en) HUMANES, RECOMBINANT INTERFERON BETA WITH IMPROVED SOLUBILITY
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
IL91322A0 (en) Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
GR3022321T3 (en) Use of il-4 to treat solid tumors
ES2009215A6 (en) IL-1B derivatives and drugs.
IL103383A0 (en) Pharmaceutical compositions containing glutamine and methods for the use thereof
IT1223990B (en) PROCEDURE FOR THE REDUCTION BY COMBUSTION OF SULFUR OXIDE AND NITROGEN OXIDE IN HIGH SULFUR CONTENT FUELS
DE3685484D1 (en)
NZ329156A (en) A method of treating harmful effects of an endogenous HGF using a modified HGf which in non-glycosylated
NO863027D0 (en) PEPTID PREPARATIONS WITH CONTINUOUS DELIVERY.
ATE98963T1 (en) SOMATOTROPIN ANALOGUES.
HUT63575A (en) Stabilized pharmaceutical composition comprising the reduced form of non-glycosylated, recombinant human interleukin-2
MY103229A (en) Porcine growth hormone analogs.
MX9702475A (en) Analogs of acidic fibroblast growth factor having enhanced stability and biological activity.
DE3162674D1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it
EP0607774A3 (en)
MY104115A (en) Linear and cyclic analogs of alpha-msh fragments with extraordinary potency